The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.
Eric Winquist
Other Remuneration - Sanofi
Srikala S. Sridhar
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Stacey Hubay
Honoraria - Sanofi
Hazem Assi
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Scott R. Berry
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Karine Alloul
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Eric Levesque
No relevant relationships to disclose
Nathalie Aucoin
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Piotr Czaykowski
No relevant relationships to disclose
Fred Saad
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi